title: [Detection of specific T cells for 264-272 and 149-157 peptides of p53 protein in peripheral blood of patients with breast cancer].
abstract: OBJECTIVE
  p53 protein is overexpressed in nearly half of all human tumours. An HLA-A2.1-restricted immunological response mediated by anti-p53 CD8+ T cells directed against the wild type p53 264-272 epitope has been demonstrated in patients with head and neck squamous carcinomas. The existence of such a response in patients with other cancer types could be determinant for the development of specific antitumour vaccines targeting the p53 protein. We aimed to determine the presence of anti-p53 specific CD8+ T cells in peripheral blood of breast cancer patients in vivo.
  
  
  METHODS
  p53 264-272-specific CD8+ T cells were directly enumerated in the peripheral circulation of patients with breast cancer using tetrameric p53 264-272/HLA-A2.1 complexes by multicolor flow cytometry. The same procedure was used to enumerate T cells specific for another HLA-A2.1 restricted wild type p53 epitope, p53 (149-157).
  
  
  RESULTS
  The 99th percentile of the concentration of anti-p53 cells in 6 HLA A2- breast cancer patients was 1/5634 (cut-off point). The median counts of anti-p53264-272 and anti-p53149-157 lymphocytes in 14 HLA A2.1+ patients were 1/2383 and 1/2335 respectively. All of the HLA A2+ patients had concentrations of anti-p53 lymphocytes above the cut-off point for at least one of the epitopes: 13/14 (93%) for p53(264-272) and 11/12 (92%) for p53(149-157).
  
  
  CONCLUSIONS
  A specific immunological response mediated by anti-p53 CD8+ T cells has been detected in patients with breast carcinoma. More studies are needed to confirm these results and to determine its usefulness for the development of p53-based vaccines.
authors.affiliation: Unidad de Oncología. Hospital San Jorge. Huesca. España. INAKI.ALVAREZ@terra.es
authors.forename: Iñaki
authors.initials: I
authors.lastname: Alvarez-Busto
authors.forename: Andreas
authors.initials: A
authors.lastname: Albers
authors.forename: María Carmen
authors.initials: MC
authors.lastname: Visus
authors.forename: José Ignacio
authors.initials: JI
authors.lastname: Mayordomo
authors.forename: Javier
authors.initials: J
authors.lastname: Sanz
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Burillo
authors.forename: Antonio
authors.initials: A
authors.lastname: Güemes
authors.forename: María Dolores
authors.initials: MD
authors.lastname: García-Prats
authors.forename: Manuel
authors.initials: M
authors.lastname: Moros
authors.forename: Albert
authors.initials: A
authors.lastname: De Leo
authors.forename: Alejandro
authors.initials: A
authors.lastname: Tres
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000097:blood* / Q000276:immunology*; D005260:Female; D006801:Humans; D018655:Lymphocyte Count; D008875:Middle Aged; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D016159:Tumor Suppressor Protein p53